Market Cap 95.55M
Revenue (ttm) 1.63M
Net Income (ttm) -29.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,820.25%
Debt to Equity Ratio 0.00
Volume 504,500
Avg Vol 853,670
Day's Range N/A - N/A
Shares Out 123.88M
Stochastic %K 46%
Beta 0.78
Analysts Strong Sell
Price Target $7.40

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
Mandalo
Mandalo Jul. 4 at 12:13 PM
$RANI WEDNESDAY JULY 8 UPCOMING NEWS 👍 The Lake Street virtual investor meeting on Wednesday, July 8, 2026, will feature key updates from Rani Therapeutics’ management. The discussion will likely highlight three main areas: ​Pipeline Progress: Status updates on the RaniPill® clinical trials and their high-profile partnership with Chugai Pharmaceutical. ​New Financial Leadership: An introduction to Nicholas Maestas, who took over as CFO on June 29, outlining his strategic financial vision. ​Cash Runway: Discussion on how the $20 million capital raised in late May extends their operational funding into Q4 2027. ​As Lake Street recently reiterated a "Buy" rating with a $9.00 price target, the session will focus heavily on long-term growth and commercialization milestones.
1 · Reply
Mandalo
Mandalo Jul. 4 at 4:16 AM
$RANI NEW CFO POSTS INTERESTING STATEMENT When Nicholas Maestas posted on LinkedIn that Rani's platform is "real," he provided a powerful insider validation to the market. As a CFO who just transitioned from Tempest Therapeutics, his statement carries significant weight for several reasons: ​Successful Due Diligence: Before leaving Tempest, Maestas thoroughly vetted Rani’s internal, non-public clinical data (like the RT-114 obesity study). "Real" means the technology actually works under the hood. ​Reputational Backing: A high-profile CFO with a UC Berkeley molecular biology background and a Wharton MBA will not risk his professional credibility on an unproven concept or market hype. ​Commercial Viability: Financially, "real" implies that manufacturing costs, patent protection, and the path to scaling the RaniPill® for multi-billion-dollar markets (like oral GLP-1s) are completely solid.
2 · Reply
Mandalo
Mandalo Jul. 3 at 6:47 AM
$RANI 34 DAYS TO EARNINGS
8 · Reply
wavw
wavw Jul. 2 at 11:49 PM
$RANI I wish more money to accumulate
1 · Reply
Hi1254
Hi1254 Jul. 2 at 3:06 PM
$RANI Something is happening here 💚
1 · Reply
Fishbonee
Fishbonee Jul. 2 at 2:54 PM
$RANI 📈
0 · Reply
Mandalo
Mandalo Jul. 1 at 9:57 PM
$RANI I HAVE NO DOUBTS ABOUT SUCCESS AND THIS IS WHY.... ​The $1.X billion partnership with Chugai Pharmaceutical—a majority-owned subsidiary of healthcare giant Roche—serves as the ultimate validation that the RaniPill is highly likely to succeed. Mega-cap pharmaceutical companies like Roche do not commit to ten-figure deals without conducting exhaustive due diligence on the underlying technology. By backing Rani Therapeutics, Chugai and Roche have effectively validated the pill's clinical data, safety profile, and high probability of technical success. For Wall Street and the medical community alike, this massive financial and strategic endorsement signals that the RaniPill is no longer just a speculative concept, but a proven breakthrough ready to disrupt the multi-billion-dollar biologics market by replacing painful injections with a simple, elegant oral alternative. THIS IS GOONABE A FUCKING GOLDMINE 🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑
0 · Reply
APRadek
APRadek Jul. 1 at 7:46 PM
$RANI any ideas!? I think they will going to disclose something special.
2 · Reply
Mandalo
Mandalo Jul. 1 at 3:52 PM
$RANI In august this year a short squeeze maybe possible here
1 · Reply
Mandalo
Mandalo Jul. 1 at 3:14 PM
$RANI Investing in Rani Therapeutics (NASDAQ: RANI) offers a compelling high-risk, high-reward opportunity as the company targets a multi-billion dollar market. By transforming painful biologic injections into a simple oral capsule via its innovative RaniPill, Rani could completely disrupt treatment for chronic conditions like Crohn’s disease and diabetes. ​While the recent $10 million share dilution caused a temporary dip, the stock has firmly established a bottom around current levels. With the capital restructuring now fully digested, the market is looking forward to upcoming clinical data. Success in these trials would not only trigger massive adoption by patients and physicians but also make Rani an incredibly attractive target for major pharmaceutical partnerships or an outright acquisition, paving the way for explosive long-term growth... All signs are on green here!
0 · Reply
Latest News on RANI
Rani Therapeutics appoints Nicholas Maestas as CFO

2026-06-29T12:20:41.000Z - 5 days ago

Rani Therapeutics appoints Nicholas Maestas as CFO

TPST


Rani Therapeutics Holdings Transcript: AGM 2026

May 28, 2026, 11:00 AM EDT - 5 weeks ago

Rani Therapeutics Holdings Transcript: AGM 2026


Rani Therapeutics Holdings Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Rani Therapeutics Holdings Quarterly report: Q1 2026


Rani Therapeutics Holdings Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Rani Therapeutics Holdings Earnings release: Q1 2026


Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing


Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025


Rani Therapeutics Holdings Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Rani Therapeutics Holdings Annual report: Q4 2025


Rani Therapeutics Holdings Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Rani Therapeutics Holdings Earnings release: Q4 2025


Rani Therapeutics promotes Javadi to Chief Technical Officer

2026-01-28T12:15:42.000Z - 5 months ago

Rani Therapeutics promotes Javadi to Chief Technical Officer


Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

2026-01-08T12:10:14.000Z - 6 months ago

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill


Rani Therapeutics Holdings Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Rani Therapeutics Holdings Earnings release: Q3 2025


Rani Therapeutics Holdings Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Rani Therapeutics Holdings Quarterly report: Q3 2025


Rani Therapeutics Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Rani Therapeutics Holdings Earnings release: Q2 2025


Rani Therapeutics Holdings Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Rani Therapeutics Holdings Quarterly report: Q2 2025


Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai


Rani Therapeutics Holdings Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q1 2025


Rani Therapeutics Holdings Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q1 2025


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024


Rani Therapeutics Holdings Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Annual report: Q4 2024


Rani Therapeutics Holdings Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q4 2024


Rani Therapeutics Holdings Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q3 2024


Rani Therapeutics Holdings Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Earnings release: Q3 2024


Rani Therapeutics Holdings Quarterly report: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2024


Rani Therapeutics Holdings Earnings release: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q2 2024


Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in August Investor Conferences


Rani Therapeutics Holdings Transcript: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Investor Update


Rani Therapeutics Holdings Press release: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Press release: Investor Update


Rani Therapeutics Holdings Slides: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Slides: Investor Update


Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences


Rani Therapeutics Holdings Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q1 2024


Rani Therapeutics Holdings Earnings release: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q1 2024


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing


Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023


Rani Therapeutics Holdings Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Annual report: Q4 2023


Rani Therapeutics Holdings Earnings release: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q4 2023


Rani Therapeutics Holdings Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q3 2023


Rani Therapeutics Holdings Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2023


Rani Therapeutics Holdings Earnings release: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Rani Therapeutics Holdings Earnings release: Q2 2023


Mandalo
Mandalo Jul. 4 at 12:13 PM
$RANI WEDNESDAY JULY 8 UPCOMING NEWS 👍 The Lake Street virtual investor meeting on Wednesday, July 8, 2026, will feature key updates from Rani Therapeutics’ management. The discussion will likely highlight three main areas: ​Pipeline Progress: Status updates on the RaniPill® clinical trials and their high-profile partnership with Chugai Pharmaceutical. ​New Financial Leadership: An introduction to Nicholas Maestas, who took over as CFO on June 29, outlining his strategic financial vision. ​Cash Runway: Discussion on how the $20 million capital raised in late May extends their operational funding into Q4 2027. ​As Lake Street recently reiterated a "Buy" rating with a $9.00 price target, the session will focus heavily on long-term growth and commercialization milestones.
1 · Reply
Mandalo
Mandalo Jul. 4 at 4:16 AM
$RANI NEW CFO POSTS INTERESTING STATEMENT When Nicholas Maestas posted on LinkedIn that Rani's platform is "real," he provided a powerful insider validation to the market. As a CFO who just transitioned from Tempest Therapeutics, his statement carries significant weight for several reasons: ​Successful Due Diligence: Before leaving Tempest, Maestas thoroughly vetted Rani’s internal, non-public clinical data (like the RT-114 obesity study). "Real" means the technology actually works under the hood. ​Reputational Backing: A high-profile CFO with a UC Berkeley molecular biology background and a Wharton MBA will not risk his professional credibility on an unproven concept or market hype. ​Commercial Viability: Financially, "real" implies that manufacturing costs, patent protection, and the path to scaling the RaniPill® for multi-billion-dollar markets (like oral GLP-1s) are completely solid.
2 · Reply
Mandalo
Mandalo Jul. 3 at 6:47 AM
$RANI 34 DAYS TO EARNINGS
8 · Reply
wavw
wavw Jul. 2 at 11:49 PM
$RANI I wish more money to accumulate
1 · Reply
Hi1254
Hi1254 Jul. 2 at 3:06 PM
$RANI Something is happening here 💚
1 · Reply
Fishbonee
Fishbonee Jul. 2 at 2:54 PM
$RANI 📈
0 · Reply
Mandalo
Mandalo Jul. 1 at 9:57 PM
$RANI I HAVE NO DOUBTS ABOUT SUCCESS AND THIS IS WHY.... ​The $1.X billion partnership with Chugai Pharmaceutical—a majority-owned subsidiary of healthcare giant Roche—serves as the ultimate validation that the RaniPill is highly likely to succeed. Mega-cap pharmaceutical companies like Roche do not commit to ten-figure deals without conducting exhaustive due diligence on the underlying technology. By backing Rani Therapeutics, Chugai and Roche have effectively validated the pill's clinical data, safety profile, and high probability of technical success. For Wall Street and the medical community alike, this massive financial and strategic endorsement signals that the RaniPill is no longer just a speculative concept, but a proven breakthrough ready to disrupt the multi-billion-dollar biologics market by replacing painful injections with a simple, elegant oral alternative. THIS IS GOONABE A FUCKING GOLDMINE 🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑
0 · Reply
APRadek
APRadek Jul. 1 at 7:46 PM
$RANI any ideas!? I think they will going to disclose something special.
2 · Reply
Mandalo
Mandalo Jul. 1 at 3:52 PM
$RANI In august this year a short squeeze maybe possible here
1 · Reply
Mandalo
Mandalo Jul. 1 at 3:14 PM
$RANI Investing in Rani Therapeutics (NASDAQ: RANI) offers a compelling high-risk, high-reward opportunity as the company targets a multi-billion dollar market. By transforming painful biologic injections into a simple oral capsule via its innovative RaniPill, Rani could completely disrupt treatment for chronic conditions like Crohn’s disease and diabetes. ​While the recent $10 million share dilution caused a temporary dip, the stock has firmly established a bottom around current levels. With the capital restructuring now fully digested, the market is looking forward to upcoming clinical data. Success in these trials would not only trigger massive adoption by patients and physicians but also make Rani an incredibly attractive target for major pharmaceutical partnerships or an outright acquisition, paving the way for explosive long-term growth... All signs are on green here!
0 · Reply
Mandalo
Mandalo Jul. 1 at 2:45 PM
$RANI Bottom is reached. From now up we go. From now game is on. This is just the beginning. Up to 7 and more I like it 🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑
0 · Reply
Jack696
Jack696 Jun. 30 at 4:51 PM
$RANI any hope for this stock?
1 · Reply
APRadek
APRadek Jun. 29 at 12:05 PM
$RANI new CFO onboard
0 · Reply
BBTAAPL
BBTAAPL Jun. 24 at 12:32 PM
$RANI when are we going to get any volume here
0 · Reply
BinaryLogic
BinaryLogic Jun. 23 at 12:49 AM
$RANI Ph-1 read outs are planned for 2H-2026 (RT-114). They have $44M in Cash/ST against $16M Total Liabilities, and a $1.0B (potential) agreement with Chugai (Roche). RaniPill (if proven successful) is not just an oral GLP1/2 candidate, but possible for ALL biologics. The 12mos PT here is 7.0 (10X) - and worth your consideration (IMO).
0 · Reply
MK10
MK10 Jun. 18 at 11:55 AM
$RANI Who thinks this one may go under .50 cents?
5 · Reply
BBTAAPL
BBTAAPL Jun. 17 at 10:15 PM
$RANI let’s get this thing back to $7!
1 · Reply
wavw
wavw Jun. 15 at 1:29 PM
$RANI short interest decreased from 13.5 to 7.38 million shares in 6 months. Hope expect some recovery in price.
0 · Reply
BinaryLogic
BinaryLogic Jun. 14 at 7:28 PM
$RANI This is one of the most Undervalued small bio-tech Companies that I profile (IMO). RaniPill® capsule is a swallowed pill designed to navigate the stomach and deliver biologic drugs directly into the intestinal wall with high bioavailability. I have spoken about this specific to GLP1/2 in the past, but the technology is an injectable alternative potentially to ALL biologics. RT-114 (GLP1/2) serves as a good case study in an incredibly strong market for the efficacy of the Ranipill and their drug candidate. The Chugai deal (licensing for hemophilia product) has more than $1.0B in potential value alone; it included up-front cash and structured milestone payments. Multi-billion dollar potential across several different verticals with a market cap of $94M. $43M in Cash against $16M in Total Liabilities with TTM burn rate of $17M. High risk, High reward, multiplier upside possible (IMO).
1 · Reply
GWaldorf5040
GWaldorf5040 Jun. 12 at 4:15 PM
$RANI time to buy the dip and flip it til .8 🤗
0 · Reply
Jack696
Jack696 Jun. 8 at 6:42 PM
$RANI how much faith do people actually have in this company?
4 · Reply
APRadek
APRadek Jun. 7 at 7:27 PM
$RANI rt-111 phase 1 took six months so rt-114 must be around the corner....
1 · Reply